MARKET

AERI

AERI

Aerie Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.25
-0.67
-3.74%
After Hours: 17.25 0 0.00% 16:19 04/16 EDT
OPEN
18.14
PREV CLOSE
17.92
HIGH
18.14
LOW
17.15
VOLUME
489.74K
TURNOVER
--
52 WEEK HIGH
21.30
52 WEEK LOW
9.01
MARKET CAP
809.32M
P/E (TTM)
-4.3236
1D
5D
1M
3M
1Y
5Y
Aerie Pharma (AERI) Received its Third Buy in a Row
After Oppenheimer and Needham gave Aerie Pharma (NASDAQ: AERI) a Buy rating last month, the company received another Buy, this time from Mizuho
SmarterAnalyst · 1d ago
Aerie Pharma (AERI) Gets a Buy Rating from Oppenheimer
In a report released today, Francois Brisebois from Oppenheimer maintained a Buy rating on Aerie Pharma (AERI), with a price target of $26.00. The
SmarterAnalyst · 2d ago
Evelo Biosciences Announces Appointments of Luca Scavo as Chief Financial Officer and Julie H. McHugh to the Board of Directors
CAMBRIDGE, Apr 15, 2021 (GLOBE NEWSWIRE via COMTEX) -- CAMBRIDGE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical...
GlobeNewswire · 3d ago
Needham Releases a Buy Rating on Aerie Pharma (AERI)
Needham analyst Serge Belanger assigned a Buy rating to Aerie Pharma (AERI) today and set a price target of $26.00. The company's shares closed last
SmarterAnalyst · 3d ago
8-K: AERIE PHARMACEUTICALS INC
(EDGAR Online via COMTEX) -- AERIE PHARMACEUTICALS INC false 0001337553 0001337553 2021-04-14 2021-04-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 3d ago
Novel Drugs and Devices to Lower Intraocular Pressure Market Landscape By Manufacturing Base, Trends, Influence factors, Revenue, Wholesalers, Opportunities and Forecasts 2020-2027
Market Insight Reports · 4d ago
Raymond James Maintains Their Hold Rating on Aerie Pharma (AERI)
SmarterAnalyst · 5d ago
Analysts Are Bullish on Top Healthcare Stocks: Aerie Pharma (AERI), Tenax Therapeutics (TENX)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aerie Pharma (AERI) and Tenax Therapeutics (TENX) with
SmarterAnalyst · 04/09 13:45
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AERI. Analyze the recent business situations of Aerie Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AERI stock price target is 27.25 with a high estimate of 50.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 262
Institutional Holdings: 60.18M
% Owned: 128.27%
Shares Outstanding: 46.92M
TypeInstitutionsShares
Increased
56
4.09M
New
21
782.68K
Decreased
47
5.00M
Sold Out
20
2.49M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Chairman/Chief Executive Officer/Director
Vicente Anido
President/Chief Operating Officer
Thomas Mitro
Co-Founder/Chief Scientific Officer
Casey Kopczynski
Chief Financial Officer/Treasurer/Secretary
Richard Rubino
General Counsel/Secretary
John LaRocca
Finance Director
Amine Sinmazisik
Vice President - Finance
Christopher Staten
Director of Marketing
Nina Ohara
Vice President
Michelle Senchyna
Other
David Hollander
Lead Director/Independent Director
Benjamin McGraw
Director
Peter McDonnell
Independent Director
Gerald Cagle
Independent Director
Richard Croarkin
Independent Director
Mechiel Du Toit
Independent Director
David Gryska
Independent Director
Michael Du Toit
Independent Director
Julie McHugh
No Data
  • All
  • Financials
  • Insiders
More
About AERI
Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan). The Company's product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Its Rhopressa is a once-daily eye drop. Rhopressa inhibits Rho kinase (ROCK), and the norepinephrine transporter (NET), which are both biochemical targets for lowering IOP. Its Roclatan is a once-daily, fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with open-angle glaucoma. The Company is engaged in conducting Phase III clinical trial for Roclatan.

Webull offers kinds of Aerie Pharmaceuticals Inc stock information, including NASDAQ:AERI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AERI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AERI stock methods without spending real money on the virtual paper trading platform.